GLP-1 Spend Eats 14.7% of Multiemployer Plan Claims, Masks Care Value
GLP-1s hit 14.7% of multiemployer claims in 2025 while Aon finds medical cost growth slowing only after year one. Trustees measuring at 12 months see spend, not savings.
TAG E-1750 · 662 words on the filing

Summary of findings
- GLP-1s for weight loss averaged 14.7% of total annual claims at multiemployer and public plans in 2025; corporate plans reported 11.4% (IFEBP 2026 survey).
- Aon tracked 192,000+ GLP-1 users 2022-2025: medical cost growth ran 6 points lower for diabetes members at 30 months, 3 points lower for weight-loss users at 18 months.
- Only one in 12 members stayed on a GLP-1 for obesity after three years (Prime Therapeutics data cited by Mercer).
- Mercer actuaries attribute a full percentage point of projected 2027 health benefit cost growth to rising GLP-1 use.
- 80%+ adherence correlated with 9-point (diabetes) and 7-point (weight loss) reductions in medical cost growth.
GLP-1 drugs for weight loss consumed 14.7% of total annual claims at multiemployer and public plans in 2025, according to the International Foundation of Employee Benefit Plans' 2026 survey. Corporate plans reported 11.4%. When one drug class carries that share, its growth rate steers the entire claims trend — and it can make a working care management program look like a failure.
A 2026 Business Group on Health survey found nearly eight in 10 employers saying GLP-1s push their health costs higher. More than half of those covering weight-management drugs expect significant clinical benefits. Few see that evidence in their aggregate claims data. The gap is a measurement problem, not necessarily a clinical one.
Why the bottom line lies right now
Pharmacy costs arrive immediately; medical savings arrive later. Mercer's actuaries estimate rising GLP-1 use accounts for a full percentage point of projected 2027 health benefit cost growth. A trustee reading only the total claims line sees the spend before the offset. Mary Bacaj, PhD, president of value-based care at Conifer Health Solutions, argues the correct move is to isolate the incremental impact of GLP-1 spending and evaluate medical utilization trends separately — without removing those expenses from the balance sheet.
The dual-lens approach is not accounting sleight of hand. It shows trustees how fast GLP-1 utilization is climbing and, separately, what other healthcare costs are doing underneath.
What did Aon actually measure?
Aon tracked more than 192,000 GLP-1 users from 2022 to 2025 against matched nonusers. For members with diabetes, medical cost growth ran six percentage points lower at 30 months. For weight-loss users, it ran three points lower at 18 months. Both improvements landed after the first year of treatment — meaning a fund reviewing GLP-1 economics at the 12-month mark sees only the pharmacy bill.
Mercer cites slow disease progression and employee turnover as reasons the immediate return stays uncertain for employers. Health funds sit in a different position. Members stay in the same fund longer, sometimes from childhood to elder years, so the fund paying for year one of therapy is more likely to still hold the member when savings arrive.
How much does adherence matter?
In the Aon data, users maintaining at least 80% adherence showed larger reductions in medical cost growth: nine points for diabetes and seven points for weight loss. The catch is staying on therapy. Prime Therapeutics data cited by Mercer found only one in 12 members remained on a GLP-1 for obesity after three years. That persistence figure deserves skepticism about any modeled long-term savings.
Nurse-led care management is the proposed countermeasure. Nurses educate members on use and side effects, coordinate between member and provider when side effects appear, and when a member stops the drug, the nurse probes why and alerts the provider to alternatives. The claim: this coordination protects both the member's health and the fund's return. No controlled trial data accompanies that assertion.
Which metrics should trustees watch instead?
First-year indicators include emergency department visits and avoidable hospitalizations per 1,000 members, plus medication adherence among GLP-1 prescribers. Over time, the measurement set should expand to cardiovascular events and diabetes-related complications. The underlying question is simple: what would the fund's financial performance look like without the incremental GLP-1 impact?
The skeptic's read is that this is an interested argument. Conifer Health Solutions sells population health management and financial risk management services to more than 250 organizations, and care management is the product being defended. The claims data cited is real enough, but the persistence problem — one in 12 at three years — could gut the long-term savings case regardless of how the accounting is framed. GLP-1 spending remains a significant ongoing commitment either way, and trustees balancing contribution decisions against multi-year clinical payback will need both lenses, and patience, before declaring victory or failure.
via ifebp.org (Original)
More from Rebecca Stone
Show full bio
Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
18 articles
Linked filings
- T-8005
- K-1191
- V-8604
- K-4995
- K-5151